Abstract
A clinical study has been performed to investigate the influence of different administration procedures on the degree of contrast enhancement of the left ventricle. The administration variables assessed included Albunex® injection rate, arm position, flushing rate and flushing fluid. Twenty-four healthy male volunteers were included. Compared to an injection rate of 1 ml/sec an injection rate of Albunex® of 2 ml/sec caused an earlier appearance of contrast in the right ventricle (1 heart beat), whereas transpulmonary passage was not influenced. Horizontal arm position caused a delay in time to peak intensity of 2 to 3 heart beats in both systole and diastole as compared to elevated arm position. Injection rate of 1 ml/sec compared to 2 ml/sec caused a higher peak intensity and mean area under the curve and a longer mean time to peak intensity and transit time. Differences varied from 6 to 230 grey level units out of mean values of 2500. All the observed differences were small and thus probably of no clinical importance.
The present study indicates that improvements in the pressure stability characteristics of the albumin microspheres in Albunex® have been achieved. This implies that a simple administration procedure can be used. It is recommended that the contrast agent, after resuspension, is injected through a three-way stop cock cannula, followed by 10 ml of saline for flushing. The cannulas or syringes used should be no smaller than 20 G. The injection rate should be 1–2 ml/sec, depending on the diameter of the cannula. By using this procedure, a reliable transpulmonary passage and left ventricular opacification may be obtained.
Similar content being viewed by others
References
Gramiak R, Shah PM. Echocardiography of the aortic root. Invest Radiol 1968; 3: 356–66.
Ten Cate FJ, Cornel JH, Widimsky P, Vletter W, Serruys P, Waaler A. Clinical experience with Albunex®: A standard echocontrast agent for intravenous and intracoronary use. Am J Card Imag 1991; 5(3): 217–23.
Sanders WE, Cheirif JB, Desir R, et al. Contrast opacification of left ventricular myocardium following intravenous administration of sonicated albumin microspheres. Am Heart J 1991; 122: 1660–5.
Crouse LJ. Sonicated serum albumin in contrast echocardiography: Improved segmental wall motion depiction and implications for stress echocardiography. Am J Cardiol 1992; 69: 42H-45H.
Shapiro JR, Reisner SA, Lichtenberg GS, Meltzer RS. Intravenous contrast echocardiography with use of sonicated albumin in humans: Systolic disappearance of left ventricular contrast after transpulmonary transmission. J Am Coll Cardiol 1990; 16: 103–7.
Feinstein SB, Cheirif J, Ten Cate FJ, et al. Safety and efficacy of a new transpulmonary ultrasound contrast agent: Initial multicenter clinical results. J Am Coll Cardiol 1990; 16: 316–24.
Keller MW, Feinstein SB, Watson DD. Successful left ventricular opacification following peripheral venous injection of sonicated contrast agent: An experimental evaluation. Am Heart J 1987; 114: 570–5.
Hellebust, Christiansen C, Skotland T. Biochemical characterization of air-filled micropheres. Biotechnol Appl Biochem (in press).
Christiansen C, Kryvi H, Sontum PC, Skotland T. Physical and biochemical of Albunex®, a new ultrasound contrast agent consisting of air-filled albumin micropheres suspended in a solution of human albumin. Biotechnol Appl Biochem (in press).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sonne, H.S., Christensen, P.D., Muan, B. et al. Left ventricular opacification after intravenous injection of albunex® . Int J Cardiac Imag 11, 47–53 (1995). https://doi.org/10.1007/BF01148953
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01148953